Shanghai Junshi Biosciences Co., Ltd. (SHJBF)
OTCMKTS · Delayed Price · Currency is USD
3.000
-0.073 (-2.38%)
At close: Jan 6, 2026
SHJBF Revenue
Shanghai Junshi Biosciences had revenue of 637.50M CNY in the quarter ending September 30, 2025, with 31.40% growth. This brings the company's revenue in the last twelve months to 2.48B, up 38.93% year-over-year. In the year 2024, Shanghai Junshi Biosciences had annual revenue of 1.95B with 29.67% growth.
Revenue (ttm)
2.48B CNY
Revenue Growth
+38.93%
P/S Ratio
13.18
Revenue / Employee
929.96K CNY
Employees
2,670
Market Cap
4.60B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.95B | 445.77M | 29.67% |
| Dec 31, 2023 | 1.50B | 49.06M | 3.38% |
| Dec 31, 2022 | 1.45B | -2.57B | -63.89% |
| Dec 31, 2021 | 4.02B | 2.43B | 152.36% |
| Dec 31, 2020 | 1.59B | 819.81M | 105.77% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 292.21M |
| Vaxart | 148.20M |
| Silence Therapeutics | 25.83M |
| Nuo Therapeutics | 2.61M |
| Northwest Biotherapeutics | 937.00K |
| ZIVO Bioscience | 209.03K |
| Arch Biopartners | 198.11K |
Shanghai Junshi Biosciences News
- 2 months ago - Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis - GlobeNewsWire
- 2 months ago - Junshi Biosciences Announces Primary Endpoints Met in JS001sc's Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC - GlobeNewsWire
- 4 months ago - Junshi Biosciences Announces FDA's Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients - GlobeNewsWire
- 5 months ago - Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints - GlobeNewsWire
- 6 months ago - TREOS Bio Partners with Charité Berlin and Junshi Biosciences to Launch Pivotal Phase II Clinical Trial in Refractory MSS Colorectal Cancer - GlobeNewsWire
- 6 months ago - Junshi Biosciences Announces 2025 Interim Financial Results and Provides Corporate Updates - GlobeNewsWire